Slide 1: Submission of Investor's Presentation to exchanges
Poly Medicure Limited Regd. Office: 232 B, 3rd Floor, Okhla Industrial Estate, Phase-Ill, New Delhi - 110 020 (INDIA) -; ' IPOLYMED T:+91-ll-33550700,47317000 E: info@polymedicure.com W: polymedicure.com CIN: L 40300DL l 995PLC066923 Date: 08 th August, 2025 Scrip Code: - 531768 Scrip Code:- POLYMED
Slide 2: Investor Presentation Q1 FY26
Investor Presentation Q1 FY26 Poly Medicure Ltd. 8th August 2025 1
Slide 3: Disclaimer
Disclaimer This presentation and the accompanying slides (“Presentation”) by Poly Medicure Limited (the “Company”) are for informational purposes only and do not constitute an offer, recommendation, or invitation to purchase or subscribe for any securities. They should not be relied upon for any con
Slide 4: Agenda
Agenda Agenda Slide # YoY Performance Summary Q1 FY26 5 Key Updates 7-13 Consolidated Financial Performance Summary 15 Sales Performance Analysis 16-17 Return ratios 18 Shareholding Pattern 19 Polymed Overview and Way forward 21-32 3
Slide 5: YoY performance summary of Q1 FY26
Agenda YoY performance summary of Q1 FY26 4
Slide 6: Consolidated Performance Summary Q1 FY26
Consolidated Performance Summary Q1 FY 26 Figs in Rs. Crs unless specified Revenue Operating EBITDA EBITDA % PAT Q1,FY26 403.2 106.1 26.3 70bps 93.1 4.8% 2.1% 25.5% Q1,FY25 384.8 103.8 27.0 74.0 RoCE* Net Cash # of Patents Increase in Sales Associates 22.4% 1,248.6 334 22 *Excludes the amount raised
Slide 7: Key Updates
Agenda Key Updates 6
Slide 8: Key Updates
Key Updates • A total of 1350+ stents were successfully implanted from April’25 to Jul’25, with positive feedback received from patients and clinicians. • Initiated an Open-label, multicentre, single arm, clinical investigation to evaluate performance and safety of RisoR Everolimus Eluting Stent Sys
Slide 9: Study on performance and safety of RisoR Stent
Study on performance and safety of RisoR Stent Study Title: An Open-label, Multicentre, Single arm, Clinical Investigation to Evaluate Performance and Safety of RisoR Everolimus Eluting Stent System (PACIFIER) Dr. Praveen Chandra Chairman – Interventional Cardiology Medanta-The Medicity, India’s Fir
Slide 10: Appointment of Mr. Vishal Baid as Executive Director approved by Shareholders
Appointment of Mr. Vishal Baid as Executive Director approved by Shareholders Some of his key contributions in the organization over the years are summarized below: • Driving automation in the production processes by identifying new technologies, helping in driving cost efficiencies and building glo
Slide 11: Approval by the Board for appointment of Mr. PK Gupta as Executive Director
Approval by the Board for appointment of Mr. PK Gupta as Executive Director Association with Poly Medicure Ltd: He joined as a senior manager in 2008 and rose to become President - Operations, leading key operational advancements. His strategic leadership significantly contributed to company’s growt
Slide 12: Enhance Usage of AI to optimize performance
Enhance Usage of AI to optimize performance In Manufacturing Processes In Learning and Development AI is being integrated into our manufacturing Our AI-powered initiative is delivering immersive training operations as we move towards smart experiences that replicate real-world customer manufacturing
Slide 13: Clinical Engagement Programs
Clinical Engagement Programs A Joint Program with INS 6 sessions , 6000+ Nurses 12
Slide 14: Participation in International Exhibitions
Participation in International Exhibitions WHX, Miami Hospitalar, Brazil Medi Pharm Expo, WHX, Kuala Lumpur Vietnam 13
Slide 15: Consolidated Financial Performance Summary
Agenda Consolidated Financial Performance Summary 14
Slide 16: Consolidated Financial Performance Summary
Consolidated Financial Performance Summary Figs in Rs. Cr. unless specified Particulars Q1 FY 26 Q1 FY 25 Growth % Revenue from Operations 403.2 384.8 4.8% Cost of Good Sold (127.2) (128.3) (0.8%) Gross Profit 276.0 256.5 7.6% Gross Profit % 68.4% 66.7% 170bps Employee Benefit Expenses (75.1) (69.5)
Slide 17: Consolidated Sales Performance Analysis
Consolidated Sales Performance Analysis Figs in Rs. Crs unless specified Particulars Q1 FY 26 Q1 FY 25 Growth % Domestic 125.7 104.7 20.1% International 275.1 277.6 (0.9%) Other Operating Revenue 2.4 2.5 (3.6%) Total Operating Revenue 403.2 384.8 4.8% Geographical Revenue Mix India 125.7 104.7 20.1%
Slide 18: Segment Wise Sales Performance Analysis
Segment Wise Sales Performance Analysis Figs in Rs. Crs unless specified Particulars Q1 FY 26 Q1 FY 25 Growth % ▪ Renal Care- Sold ~130 Dialysis Infusion Therapy 251.8 256.2 -1.7% machine from Apr’25 to Jul’25, expanding presence to ~170 cities Renal 43.5 29.8 46.2% through strategic alliance with t
Slide 19: Return Ratios
Return Ratios ROCE ROE * 23% 23%* 22%** 19% 19% 18%* 17%** 15% FY 23 FY 24 FY 25 Jun'25 FY 23 FY 24 FY 25 Jun'25 * Excludes the amount raised through QIP in August 2024, EBIT has been computed after excluding the treasury income generated from the QIP Funds ** Calculated based on trailing 12 months
Slide 20: Shareholding Pattern as on June 30th 2025
Shareholding Pattern as on June 30th 2025 Others 14.5% Insurance FPI Companies 11.4% 2.7% AIF Promoter and 1.7% Promoter Group 62.4% Mutual Funds 7.3% 19
Slide 21: Corporate Overview
Agenda Corporate Overview 20
Slide 22: Polymed Key Differentiators
Polymed Key Differentiators ▪ Legacy – Operating since 1997 ▪ Leadership – Second fastest growing Medtech Company in India in terms of revenue * ▪ Focus on innovation : Granted 334 patents in India and globally ▪ Manufacturing powerhouse – Backward integrated manufacturing facilities with annual cap
Slide 23: Polymed at a Glance
Polymed at a Glance 12 12 Manufacturing Plants Specialities Across 4 countries 125+ Countries 200+ Medical Devices 3000+ Employee Base 530+ Sales Associates 334 Patents Granted 900+ 1.8 Billion+ Devices Manufacturing Capacity Distributors across India & Globally Per year 22
Slide 24: Navigating Our Journey
Navigating Our Journey Polymed’s Path of Milestones and Triumphs 2024 Cardiology & Critical Care PolyHealth Medical 2021 Inc. (US subsidiary of Poly Medicure 2019 2016 Ltd.) 2011 2003 2007 Gamma 2025 Acquired Plan1 Company listed New R&D Health, Italy Sterilization Joint Venture in Haridwar in Natio
Slide 25: Awards & Accolades
Awards & Accolades Mr Himanshu Baid, MD, Poly Medicure Hurun India 2024 List of Himanshu Baid, MD, Poly Medicure Medical Devices Provider of the Year EY Entrepreneur of the Year Award 2024 - India's 500 Most Valuable Companies Healthcare Entrepreneur of the Year 2025 2025 by Financial Express Lifesc
Slide 26: Navigating the Path
Navigating the Path Building Tomorrow’s Healthcare Solutions Started In 2028 1997 2002-09 2011-19 2020-24 2025 - 27 & beyond Commencement Product and facility New R&D Center, of Manufacturing expansion Acq of Plan 1 Health, Operation New Manufacturing › Launched › Prioritize the › Through a Plants d
Slide 27: Polymed's Ecosystem (Manufacturing Process)
Polymed’s Ecosystem (Manufacturing Process) Clinical Support Distribution Network Sales & Marketing Product Concept Product Product Design Manufacturing Rapid Prototyping Product Packaging Regulatory Sterilization Compliance Tool Design Tool Manufacturing 26
Slide 28: Our Innovations Deliver Care to Key Clinical Specialties
Our Innovations Deliver Care to Key Clinical Specialties Cardiology Anaesthesia & Respiratory Care Transfusion System Oncology Vascular Access Infusion Therapy Gastroenterology Diagnostics Urology Dialysis & Renal Care Surgery & Wound Drainage Critical Care 27
Slide 29: Diving into our Product Portfolio
Diving into our Product Portfolio Vascular Pre-filled Access Disinfecting Saline Syringe Central Venous Safety Introducer Safety Winged IV Cannula Cap IV Sets Three Way Stop Cock Catheters Needle Infusion Set Infusion Therapy Extension Lines with Infusion Set with Three Way Stop Cock Arterial Blood
Slide 30: Cardiology, Surgery and Wound Drainage, Respiratory Care Products
Cardiology Diagnostic Catheter PTCA Balloon PTCA Balloon DES Hydrophilic Guidewire PTFE Coated Guidewire Dilation Catheter SC Dilation Catheter NC Guiding Catheter Closed Wound Surgery and Suction Unit Wound Drainage Closed Wound Centesis Catheter High Pressure Redon Under Water Thoracic Yankauer Ya
Slide 31: Polymed's Manufacturing Footprint
Polymed's Manufacturing Footprint 12 Facilities across 3 continents 117,Faridabad, India IMT 1,Faridabad, India SEZ 2, Jaipur, India Laiyang-qingdao, 104-105,Faridabad Amaro, Italy Haridwar Plant, India IMT 2, Faridabad 115-116, Faridabad SEZ 1 Jaipur, India R & D Centre, India Assuit, Egypt China P
Slide 32: Way Forward
Way Forward Research & Development ▪ Targeted R&D investments towards transformative therapeutic areas, aiming towards innovations Emphasizing Inorganic Growth ▪ Integration of AI and IoT technologies to enhance efficiency & precision Strategic Alliances to foster synergies and expanding market reac
Slide 33: Towards our Commitment to a Sustainable World
Towards our Commitment to a Sustainable World Approx. 50% facilities are certified under Achieved ~20% reduction in Scope 1 ISO 14001:2015 (Q1 FY25 vs. Q1 FY24) ENVIRONMENTAL MANAGEMENT SYSTEM SCOPE 1 EMISSION Q1 FY 25- 764 MW ▪ Annual Health check-up of 180 employees ▪ One on one consultation with
Slide 34: Thank You
Thank You For any investor related queries reach us at: aayur.verma@polymedicure.com 33